You can buy or sell Foamix and other stocks, options, ETFs, and crypto commission-free!
Foamix Pharmaceuticals Ltd. Ordinary Shares, also called Foamix, is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Read More Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
52 Week High
52 Week Low
Seeking AlphaMar 1
Foamix Pharmaceuticals' (FOMX) CEO David Domzalski on Q4 2018 Results - Earnings Call Transcript
Foamix Pharmaceuticals (NASDAQ:FOMX) Q4 2018 Results Earnings Conference Call March 1, 2019 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Officer Iain Stuart - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Ken Cacciatore - Cowen and Company Sudan Loganathan - Cantor Fitzgerald Patrick Dolezal - LifeSci Capital Op...
Stock Price, News, & Analysis for Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-sev...
Yahoo FinanceFeb 21
Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
The market expects Foamix (FOMX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
Expected May 7, After Hours